Cleveland Clinic researchers collaborate with international team to uncover how the body responds to life-threatening disease from herpes simplex virus 1
Researchers revealed novel genetic alterations and immune mechanisms in a child that was hospitalized with herpes encephalitis.
Cleveland Clinic Receives $7.9 Million Grant from NIH to Form Radiation Oncology-Biology Integration Network (ROBIN)
Precision cancer medicine is the goal of a new multidisciplinary study, led by Dr. Tim Chan, examining radiation therapy combined with targeted therapy
Florida Research and Innovation Center Team Discovers New Signal for Triggering Human Immune Response
Cytoskeleton disturbance is key in inducing immune response; multi-trigger immune system signaling holds implications for vaccines, therapeutics.
Cleveland Clinic Receives $2.9 Million for Additional Research on Emerging Tick-borne Virus Pathogen
Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).
Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development
In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.
Lerner-Developed Flow Cytometry Best Practices Lay Groundwork for Global Recommendations
Dr. Asosingh’s team developed new Shared Resource Laboratory (SRL) guidelines, including user consultations, to ensure experimental success and accuracy.
Researchers to Study if Non-Coding SARS-CoV-2 Genetic Material Can Offer Insights into New COVID-19 Therapies
Led by Dr. Fox, researchers from Cleveland and Florida will collaborate to investigate if certain regions of SARS-CoV-2 genetic material, called non-coding RNA, can be targeted to treat or prevent COVID-19 infection.
Dr. Michaela Gack Receives Prestigious NIH Director’s Pioneer Award
Dr. Gack has received a five-year, $5.6 million award as part of NIH’s High-Risk, High-Reward Research Program to study novel approaches to target viral pathogens, which may help inform the development of new antiviral therapies.
New Study From Cleveland Clinic Pathogens Researchers Points to Novel Drug Target for Treating COVID-19
Dr. Gack and other FRIC researchers discovered that a coronavirus enzyme blocks the activity of a previously undefined host immune response, suggesting therapeutics that inhibit the enzyme may help treat COVID-19.
$2.8M Grant Awarded to Develop Vaccine to Counter Emerging Tick-Borne Virus
The funds, the first to go to Cleveland Clinic’s new Center for Global and Emerging Pathogens, will support Dr. Jung’s work to test four vaccine candidates against the virus that causes severe fever with thrombocytopenia.
Cleveland Clinic Names Chair of Department of Cancer Biology
Jae Jung, PhD, a renowned expert in virus-induced cancers and immunology research, will lead Lerner Research Institute’s Department of Cancer Biology and will also serve as director of Cleveland Clinic’s Center for Global and Emerging Pathogens Research.
Cleveland Clinic Florida Opens Florida Research and Innovation Center
The new center, which will complement and expand research underway at Lerner Research Institute, will focus on research related to cancer and infectious diseases, including COVID-19 and immune system response.